The number of jobs lost due to the coronavirus shutdown continue to mount, with the latest weekly total of Americans applying for unemployment benefits coming in at more than 1.4 million, yet again. Yahoo Finance's Zack Guzman and Heidi Chung discuss....
The biggest initial public offering of 2020 might surprise you. It's Royalty Pharma (NASDAQ:RPRX), which as the name suggests, owns royalties on drugs from other pharmaceutical companies. So far, it's been a winner: even with a recent pullback, RPRX stock trades 66% above its IPO price.Source: Shutterstock I covered Royalty Pharma on my Moneyline podcast just last week. But since then, the story has seen a bit of a change. After a sharp post-IPO rally -- at the high, the stock had doubled -- RPRX has pulled back. Shares are down almost 10% in the past few days, bringing valuation in.The pullback isn't surprising. Indeed, last week I predicted precisely such a move after the strong rally out of the gate. And I'd expect, and hope for, additional weakness. There's an intriguing story here -- but it's not quite perfect. A cheaper price certainly would help.InvestorPlace - Stock Market News, Stock...
(Bloomberg) -- Boeing Co. hasn’t told employees, but the company is pulling the plug on its hulking 747 jumbo jet, ending a half-century run for the twin-aisle pioneer.The last 747-8 will roll out of a Seattle-area factory in about two years, a decision that hasn’t been reported but can be teased out from subtle wording changes in financial statements, people familiar with the matter said.It’s a moment that aviation enthusiasts long have dreaded, signaling the end of the double-decker, four-engine leviathans that shrank the world. Airbus SE is already preparing to build the last A380 jumbo, after the final convoy of fuselage segments rumbled to its Toulouse, France, plant last month.Yet for all their popularity with travelers, the final version of the 747 and Europe’s superjumbo never caught on commercially as airlines turned to twin-engine aircraft for long-range flights. While Boeing’s hump-nosed freighters will live on, the fast-disappearing A380 risks going...
AbbVie (NYSE:ABBV) stock is both cheap and has a very attractive dividend yield. In addition, this pharmaceutical company's growth prospects are high, now that its purchase of Allergan is closed.Source: Piotr Swat / Shutterstock.com For example, the stock trades on a forward earnings ratio of just 9.2 times 2020 expected earnings. It is even lower with 2021 earnings prospects.In addition, the $4.72 per share annual dividend is very attractive to most investors for several reasons. For one, the dividend yield for ABBV stock is much higher than the average stock.InvestorPlace - Stock Market News, Stock Advice & Trading TipsSecondly, the dividend is likely to keep on growing at a nice pace. For example, on June 17 AbbVie declared a $1.18 quarterly dividend for the third time. After the fourth quarterly dividend at this rate, I suspect the company will raise the dividend in Q4. According to Seeking Alpha, AbbVie has had...
